Kent Thoelke is a member of The Geneva Foundation’s Scientific Advisory Board.
Executive Vice President and Chief Scientific Officer
PRA Health Sciences
Area of Expertise: Hematology, Oncology
Kent Thoelke currently is the Executive Vice President and Chief Scientific Officer of PRA International. Mr. Thoelke has held several Vice President position at PRA including Global Product Development and Therapeutic Expertise. Mr. Thoelke sits on the Executive team of PRA International, a global contract research organization that conducts clinical trials in over 80 countries. In his role he provides scientific, medical and strategic oversight to pharmaceutical and biotech companies focused on global drug development covering all therapeutic areas. His focus is utilizing technologic innovation and medical informatics to advance clinical drug development globally in an effort to help bring novel medications to market.
Prior to joining PRA, Mr. Thoelke was Executive Director of Corporate Development and Global Drug Development for Pharmaceutical Product Development, Inc. (PPD). Under his leadership, the company successfully expanded its global therapeutic/strategic development program across all major therapeutic areas.
Mr. Thoelke has over 20 years of experience in all aspects of the global drug development and device industry with particular expertise in the execution of all aspects of global hematology/oncology studies. Having visited over 40 countries, he is familiar with the global drug development environment, and has established relationships with therapeutic experts in numerous indications around the world. Mr. Thoelke has spoken widely regarding the current landscape of clinical trial recruitment and its effect on drug development timelines. He is active in pursuing novel technologies and strategies to move the current clinical drug development paradigm towards a more focused evidence-based strategy.